PT - JOURNAL ARTICLE AU - Krüger, Clara AU - Lim, Shen-Yang AU - Buhrmann, Alissa AU - Fahrig, Fenja L. AU - Gabbert, Carolin AU - Bahr, Natascha AU - Madoev, Harutyun AU - Marras, Connie AU - Klein, Christine AU - Lohmann, Katja TI - MDSGene update and expansion: Clinical and genetic spectrum of <em>LRRK2</em> variants in Parkinson’s disease AID - 10.1101/2024.12.10.24318787 DP - 2024 Jan 01 TA - medRxiv PG - 2024.12.10.24318787 4099 - http://medrxiv.org/content/early/2024/12/10/2024.12.10.24318787.short 4100 - http://medrxiv.org/content/early/2024/12/10/2024.12.10.24318787.full AB - Pathogenic variants in the LRRK2 gene are one of the most commonly identifiable monogenic causes of Parkinsońs disease (PD, PARK-LRRK2). This systematic MDSGene literature review comprehensively summarizes published demographic, clinical, and genetic findings related to potentially pathogenic LRRK2 variants (https://www.mdsgene.org/). Recent insights on LRRK2’s kinase activity have been incorporated for pathogenicity scoring.Data on 7,885 individuals with 292 different variants were curated, including 3,296 patients with PD carrying 205 different potentially disease-causing LRRK2 variants. The initial MDSGene review covered only 724 patients carrying 23 different LRRK2 variants. Missingness of phenotypic data in the literature was high, hampering the identification of detailed genotype-phenotype correlations. Notably, the median age at onset in the patients with available information was 56 years, with approximately one-third having PD onset &lt;50 years. Tremor was the most frequently reported initial symptom and more frequent than reported in other dominantly inherited forms of PD. Of the 205 potentially disease-causing variants, 14 (6.8%) were classified as pathogenic, 8 (3.9%) as likely pathogenic, and the remaining 183 (89.3%) as variants of uncertain significance (VUS). The pathogenic p.G2019S variant was the most frequent pathogenic variant, followed by p.R1441G and p.R1441C, accounting for &gt;80% of patients, with Tunisia, Spain, and Italy contributing about half of patients.This systematic review represents the largest database on PARK-LRRK2 to date and provides an important resource to improve precision medicine. Given their high frequency, a better interpretation of the pathogenicity of VUS is needed for selection and stratification of patients in clinical trials.Competing Interest StatementThe authors do not have any conflict of interest. S.Y.L. has received grants from and served as a consultant for the Michael J. Fox Foundation. C.K. serves as a medical advisor to Centogene and Takeda and previously to Retromer Therapeutics and has received Speakers' honoraria from Desitin and Bial. C.M. has received honoraria from the Parkinson's Foundation.Funding StatementThis work was supported by the International Parkinson and Movement Disorder Society, the Parkinson's Foundation, and the University of Luebeck.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data of our review article originated from published literature and were obtained through a systematic literature review using PubMed (https://pubmed.ncbi.nlm.nih.gov/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.mdsgene.org/